Cost Effectiveness and Cost Utility of Adjuvant Interferon in Cutaneous Melanoma: A Review

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.9, 2004-01, pp. : 569-580

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-effectiveness of interferon-α₂ as adjuvant therapy in malignant melanoma

By Lafuma Antoine Grob Jean Jacques

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 3, 2003-03 ,pp. : 343-349

Informa Healthcare

Access to resources Recommend Favorite

Focus on cost-effectiveness, utility studies `could be a mistake'

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 364, 2002-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Cost effectiveness of adjuvant chemotherapy a generation game?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 634, 2011-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair Millward Michael J.

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

By Norum Jan

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1617-1625

Informa Healthcare

Access to resources Recommend Favorite